165 related articles for article (PubMed ID: 19251971)
1. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.
Sofaer N; Thiessen C; Goold SD; Ballou J; Getz KA; Koski G; Krueger RA; Weissman JS
J Med Ethics; 2009 Mar; 35(3):183-8. PubMed ID: 19251971
[TBL] [Abstract][Full Text] [Related]
2. Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in Western Kenya.
Shaffer DN; Yebei VN; Ballidawa JB; Sidle JE; Greene JY; Meslin EM; Kimaiyo SJ; Tierney WM
J Med Ethics; 2006 Jan; 32(1):55-60. PubMed ID: 16373525
[TBL] [Abstract][Full Text] [Related]
3. Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.
Sofaer N
Bioethics; 2014 Nov; 28(9):456-71. PubMed ID: 24602060
[TBL] [Abstract][Full Text] [Related]
4. Post-trial responsibilities beyond post-trial access.
Cho HL; Danis M; Grady C
Lancet; 2018 Apr; 391(10129):1478-1479. PubMed ID: 29676274
[No Abstract] [Full Text] [Related]
5. The challenge of assuring continued post-trial access to beneficial treatment.
Grady C
Yale J Health Policy Law Ethics; 2005; 5(1):425-35. PubMed ID: 15742586
[No Abstract] [Full Text] [Related]
6. Post-trial access to antiretrovirals: who owes what to whom?
Millum J
Bioethics; 2011 Mar; 25(3):145-54. PubMed ID: 19594728
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
Buckley M; O'neil C
J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
[TBL] [Abstract][Full Text] [Related]
9. Availability of post-trial access in clinical trials: a review of clinical trial protocols submitted to the research ethics board of the University of the Philippines Manila.
Jimenez EB; Virtudazo JMP; Torres CE; Bernabe RD
Curr Med Res Opin; 2019 Nov; 35(11):1849-1855. PubMed ID: 31311340
[No Abstract] [Full Text] [Related]
10. Implementing post-trial access plans for HIV prevention research.
Paul A; Merritt MW; Sugarman J
J Med Ethics; 2018 May; 44(5):354-358. PubMed ID: 29487116
[TBL] [Abstract][Full Text] [Related]
11. Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study.
Pace C; Grady C; Wendler D; Bebchuk JD; Tavel JA; McNay LA; Forster HP; Killen J; Emanuel EJ
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):837-41. PubMed ID: 16989607
[TBL] [Abstract][Full Text] [Related]
12. Participant views and experiences of participating in HIV research in sub-Saharan Africa: a qualitative systematic review.
Nalubega S; Evans C
JBI Database System Rev Implement Rep; 2015 Jun; 13(5):330-420. PubMed ID: 26455613
[TBL] [Abstract][Full Text] [Related]
13. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.
Hutt LE
Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Improving subject recruitment by maintaining truly informed consent: a practical benefit of disclosing adverse clinical trial results.
Shah KR; Batzer FR
Am J Bioeth; 2009 Aug; 9(8):36-7. PubMed ID: 19998157
[No Abstract] [Full Text] [Related]
16. Justifying community benefit requirements in international research.
Hughes RC
Bioethics; 2014 Oct; 28(8):397-404. PubMed ID: 23025255
[TBL] [Abstract][Full Text] [Related]
17. Post-trial access to study medication: a Brazilian e-survey with major stakeholders in clinical research.
Dainesi SM; Goldbaum M
J Med Ethics; 2012 Dec; 38(12):757-62. PubMed ID: 22915826
[TBL] [Abstract][Full Text] [Related]
18. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries?
Zong Z
J Med Ethics; 2008 Mar; 34(3):188-92. PubMed ID: 18316461
[TBL] [Abstract][Full Text] [Related]
19. Healthy volunteers' perceptions of risk in US Phase I clinical trials: A mixed-methods study.
Fisher JA; McManus L; Cottingham MD; Kalbaugh JM; Wood MM; Monahan T; Walker RL
PLoS Med; 2018 Nov; 15(11):e1002698. PubMed ID: 30457992
[TBL] [Abstract][Full Text] [Related]
20. Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials.
Haire B; Jordens C
Dev World Bioeth; 2015 Aug; 15(2):85-97. PubMed ID: 26193849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
